Incidence of Shingles Up for Patients Aged 50 and Older With Past COVID-19 Diagnosis
For adults aged 50 years or older, those with a COVID-19 diagnosis have an increased risk for developing herpes zoster.
Varicella Zoster Virus
Update on the Safety and Efficacy of MMR/MMRV Vaccines in Pediatric Patients
Researchers conducted a study to assess the effectiveness, safety, and adverse effects associated with the measles-mumps-rubella and varicella vaccines in children aged 15 years and younger.
Shingrix Approved to Prevent Shingles in Immunocompromised Adults
Previously, the vaccine was only approved for adults 50 years of age and older.
Universal Vaccination Program Corresponds to Decrease in Overall Pediatric Herpes Zoster Cases
Investigators sought to assess the impact of age and vaccination status on rates of herpes zoster in a pediatric population.
2008 to 2018 Saw Increase in Shingles Vaccination in Over 60s
From 2008 to 2018, there was an increase in shingles vaccination among adults aged 60 years and older, with demographic, socioeconomic, and geographic variations in vaccination rates.
Initial Presentation Not Associated With Pathogen in Infectious Encephalitis
A team of French investigators sought to identify factors that could be considered predictive of the etiology of infectious encephalitis.
Herpes Zoster in Healthy Children Linked to Varicella-Zoster Vaccination
The morphology of the lesions included erythematous papules, pseudovesicles, and plaques, with associated pain in 2 and pruritus in 3 patients; systemic symptoms ranged from none to low‐grade fevers, upper respiratory symptoms, and joint pain.
Vaccine Lessens Incidence of Herpes Zoster Complications in Immuncompetent Older Adults
Researchers reviewed clinical trial data to evaluate the efficacy of herpes zoster subunit vaccine in preventing complications, hospitalizations, and deaths.
ACIP: New Recommendations for Herpes Zoster Vaccine Administration
The Advisory Committee on Immunization Practices has provided 3 new recommendations to supplement its original 2008 report, as well as a cost-effectiveness analysis from the CDC.
VZV Vaccine Promising in Immunocompromised Patients With Herpes Zoster
Phase 3 study looked at the safety, tolerability, efficacy, and immunogenicity of inactivated VZV Vaccine in recipients of auto-HSCT.
- Loading...
Loading...
Next post in Skin Infections
Loading... 
Loading...